JP2023532278A5 - - Google Patents
Info
- Publication number
- JP2023532278A5 JP2023532278A5 JP2022579946A JP2022579946A JP2023532278A5 JP 2023532278 A5 JP2023532278 A5 JP 2023532278A5 JP 2022579946 A JP2022579946 A JP 2022579946A JP 2022579946 A JP2022579946 A JP 2022579946A JP 2023532278 A5 JP2023532278 A5 JP 2023532278A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- seq
- tcr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025136019A JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044150P | 2020-06-25 | 2020-06-25 | |
| US63/044,150 | 2020-06-25 | ||
| PCT/US2021/039262 WO2021263211A2 (en) | 2020-06-25 | 2021-06-25 | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136019A Division JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023532278A JP2023532278A (ja) | 2023-07-27 |
| JP2023532278A5 true JP2023532278A5 (cg-RX-API-DMAC7.html) | 2023-08-24 |
| JP7781085B2 JP7781085B2 (ja) | 2025-12-05 |
Family
ID=79281973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579946A Active JP7781085B2 (ja) | 2020-06-25 | 2021-06-25 | 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
| JP2025136019A Pending JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136019A Pending JP2025166212A (ja) | 2020-06-25 | 2025-08-18 | 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230250149A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171587A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7781085B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116322750A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021297458B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188143A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021263211A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4519675A4 (en) * | 2022-05-03 | 2026-04-08 | 3T Biosciences Inc | T-LYMPHOCYTE TARGET DISCOVERY |
| WO2023228968A1 (ja) * | 2022-05-25 | 2023-11-30 | 国立大学法人東海国立大学機構 | ポリヌクレオチド |
| WO2024163292A1 (en) * | 2023-01-30 | 2024-08-08 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
| WO2024263821A2 (en) * | 2023-06-20 | 2024-12-26 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| AU2024312524A1 (en) * | 2023-06-20 | 2026-01-22 | Immunova Therapeutics Llc | Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains |
| WO2025084880A1 (ko) * | 2023-10-20 | 2025-04-24 | 주식회사 이온셀 | Ct83 항원에 결합하는 car-t 세포 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2951202T (pt) * | 2013-01-29 | 2020-07-07 | Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch | Moléculas de ligação de alta avidez que reconhecem mage-a1 |
| CA2912389C (en) * | 2013-06-10 | 2020-01-28 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods and compositions for reducing immunosupression by tumor cells |
| EP3104866A4 (en) * | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| RU2716716C2 (ru) | 2014-10-27 | 2020-03-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии |
| KR102546296B1 (ko) * | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| MA44907A (fr) * | 2015-09-11 | 2018-07-18 | Agenus Inc | Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation |
| MX2018008416A (es) * | 2016-01-08 | 2019-11-11 | Univ California | Polipéptidos heterodímericos condicionalmente activos y métodos para su uso. |
| AU2017232431A1 (en) * | 2016-03-15 | 2018-09-20 | Cancer Research Technology Limited | Chimeric antigen receptor |
| US20210079061A1 (en) | 2018-02-26 | 2021-03-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| WO2019241688A1 (en) * | 2018-06-14 | 2019-12-19 | Bluebird Bio, Inc. | Cd79b chimeric antigen receptors |
| CN113454110B (zh) * | 2018-10-23 | 2024-07-02 | 里珍纳龙药品有限公司 | Ny-eso-1 t细胞受体和其使用方法 |
-
2021
- 2021-06-25 AU AU2021297458A patent/AU2021297458B2/en active Active
- 2021-06-25 JP JP2022579946A patent/JP7781085B2/ja active Active
- 2021-06-25 WO PCT/US2021/039262 patent/WO2021263211A2/en not_active Ceased
- 2021-06-25 US US18/002,969 patent/US20230250149A1/en active Pending
- 2021-06-25 CN CN202180056522.1A patent/CN116322750A/zh active Pending
- 2021-06-25 EP EP21827918.0A patent/EP4171587A4/en active Pending
- 2021-06-25 CA CA3188143A patent/CA3188143A1/en active Pending
-
2025
- 2025-08-18 JP JP2025136019A patent/JP2025166212A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| US11168150B2 (en) | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA | |
| KR102048477B1 (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
| CN108610420B (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| AU2016305697B2 (en) | Novel anti-PD-1 antibodies | |
| JP6588534B2 (ja) | 抗pd−1のモノクローナル抗体およびその獲得方法 | |
| NL2014935B1 (en) | T cell receptor like antibodies having fine specificity. | |
| AU2017414149B2 (en) | Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) | |
| US10618962B2 (en) | Anti-CTLA4 antibodies | |
| JP7395471B2 (ja) | 改変抗SIRPa抗体及びその使用 | |
| US20230076027A1 (en) | Hhla2 as a novel inhibitor of human immune system and uses thereof | |
| CA3066779A1 (en) | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof | |
| JP2018529327A5 (cg-RX-API-DMAC7.html) | ||
| KR20190105112A (ko) | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 | |
| CN101541834A (zh) | 癌症的预防和/或治疗剂 | |
| KR102048476B1 (ko) | 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도 | |
| CN121248790A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| JP2022542559A5 (cg-RX-API-DMAC7.html) | ||
| CN121427832A (zh) | 细胞 | |
| CA3145857A1 (en) | Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof | |
| CN108948194A (zh) | 一种新的ctla-4单克隆抗体 | |
| CN119278213A (zh) | 针对ctla-4的抗体及其使用方法 | |
| JP2024105603A (ja) | CARライブラリおよびscFvの製造方法 | |
| EP3875478A1 (en) | Novel non-immunogenic chimeric antigen receptors and uses thereof |